ArticleDrug safety2012
Safety monitoring of herb-drug interactions: a component of pharmacovigilance.
Article in Drug safety, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Estimating Adverse Events Associated With Herbal Medicines Using Pharmacovigilance Databases: Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2024Pooled it
- Appetite-Suppressing and Satiety-Increasing Bioactive Phytochemicals: A Systematic Review.Nutrients · 2019Pooled it
- Fraxetin Inhibits UGT1A1 and UGT1A9 Activities In Vitro: Inhibition Kinetics, Molecular Dynamics Simulation, and Prediction of Herb-Drug Interaction Risk.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Comprehensive Insights into Natural Bioactive Compounds: From Chemical Diversity and Mechanisms to Biotechnological Innovations and Applications.ChemistryOpen · 2026Review
- Patterns of herbal medicine utilization for hypertension during the Sudanese crisis of 2025.Scientific reports · 2026Article
- An Update on Clinically Evaluated Medicinal Plants for Psoriasis Management.Current drug discovery technologies · 2025Review
- Safety Aspects of Herb Interactions: Current Understanding and Future Prospects.Current drug metabolism · 2024Review
- Signal Detection and Assessment of Herb-Drug Interactions: Saudi Food and Drug Authority Experience.Drugs - real world outcomes · 2023Article
- Suspected cutaneous adverse drug reactions reported with traditional medicines: analysis of data for United Nations Asia region from WHO VigiBase.Frontiers in pharmacology · 2023Article
- The Safety of Herbal Medicines (Phytovigilance) from Community Pharmacists' Perspective: A Cross-Sectional Study.Turkish journal of pharmaceutical sciences · 2022Article
- Analysis of Hepatobiliary Disorder Reports Associated With the Use of Herbal Medicines in the Global Suspected ADR Database Vigibase.Frontiers in pharmacology · 2019Article
- Critical evaluation of causality assessment of herb-drug interactions in patients.British journal of clinical pharmacology · 2018Review
- Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences.European journal of drug metabolism and pharmacokinetics · 2016Review
- Identification and evaluation of drug-supplement interactions in Hungarian hospital patients.International journal of clinical pharmacy · 2014Article
- Herbal medicines in Brazil: pharmacokinetic profile and potential herb-drug interactions.Frontiers in pharmacology · 2014Review
- Chinese patent medicine tongxinluo capsule for hypertension: a systematic review of randomised controlled trials.Evidence-based complementary and alternative medicine : eCAM · 2014Article
- Challenges and guidelines for clinical trial of herbal drugs.Journal of pharmacy & bioallied sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug reactions, including those resulting from interactions between herbal medicines and conventional drugs, are a public health problem worldwide. The need for pharmacovigilance for herb-drug interactions (HDIs) is essential for the identification and assessment of risks of using herbal products (questionable safety, efficacy and quality), which are not always tested with rigor, or often not subject to approval by regulatory agencies. Spontaneous and active surveillance conducted by national pharmacovigilance centres permits a rapid detection of potentially harmful combinations of products. The incidence and prevalence of HDIs are difficult to predict because of the underreporting of adverse effects. It is important for health professionals, consumers, regulatory authorities and suppliers of herbal medicines to be aware of the possible adverse effects and drug interactions caused when herbal medicines are co-administered with conventional drugs. National pharmacovigilance centres continue to play a significant role in increasing awareness of drug safety, in this case with HDIs. The authors' objective for this paper is to provide awareness among policy makers responsible for the design of appropriate pharmacovigilance practices and therefore to highlight the importance of pharmacovigilance in the safety monitoring of HDIs.
Indexed as
Identifiers
22876741What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.